Skip to main content
Government of Quebec
Institut national de santé publique du Québec
Français
FR
Home
Navigation principale
The Institute
The Institute
About us
About us
Products and services offered
Back
Contact us
Contact us
Workplaces
Back
Exit
Back
Expertise
Expertise
Information management and analysis
Information management and analysis
Deprivation
Deprivation
Indices of multiple and multidimensional deprivation
Material and Social Deprivation Index
Back
Back
Individual and community development
Individual and community development
Perinatal and early childhood
Perinatal and early childhood
From Tiny Tot to Toddler
Back
Back
Lifestyles
Lifestyles
Alimentation
Alimentation
Health-promoting environments
Back
Back
Psychoactive substances, tobacco and gambling
Psychoactive substances, tobacco and gambling
Drugs and medicines
Drugs and medicines
Opioid overdoses
Back
Tobacco and electronic cigarettes
Tobacco and electronic cigarettes
Science Watch : Tobacco Control
Back
Back
Infectious diseases
Infectious diseases
Respiratory infectious diseases
Respiratory infectious diseases
Données des virus respiratoires
COVID-19 (coronavirus)
Back
Prevention and control of healthcare-associated infections
Prevention and control of healthcare-associated infections
Nosocomial infections
Back
Travel-health
Travel-health
Health tips for travellers
Back
Zoonoses and emerging diseases
Zoonoses and emerging diseases
Diseases transmitted by ticks
Back
Back
Occupational health
Occupational health
Work-related respiratory diseases
Work-related respiratory diseases
Asbestos
Back
Psychosocial risks in the workplace
Psychosocial risks in the workplace
Let's get started
Back
Back
Indigenous Health
Indigenous Health
Research Monitoring
Research Monitoring
Methodology for Indigenous Health Research Monitoring
Back
Nunavik Inuit Health Survey 2004
Back
Environmental Health
Environmental Health
Air quality
Air quality
Indoor air
Back
Back
Safety, violence and injury prevention
Safety, violence and injury prevention
Community safety promotion
Community safety promotion
Methods and tools
Back
Prevention of interpersonal violence
Prevention of interpersonal violence
Sexual Violence
Rapport québécois sur la violence et la santé
Back
Back
Exit
Back
Services
Services
Centre de toxicologie du Québec
Centre de toxicologie du Québec
About the CTQ
About the CTQ
Contact us
Back
Services
Services
Test catalog
Analysis request forms
Shipping samples
PayPal Bill Payment
Back
External quality assessment schemes
External quality assessment schemes
AMAP: AMAP Ring Test for Persistent Organic Pollutants in Human Serum
Creatinine: Interlaboratory Comparison Program for Measurement of Serum Creatinine
OSEQAS: External Quality Assessment Scheme for Organic Substances in Urine
PCI: Interlaboratory Comparison Program for Metals in Biological Matrices
QMEQAS: Quebec Multielement External Quality Assessment Scheme
Back
Back
Infectious diseases
Infectious diseases
Blood-Borne Infection Risk Assessment Unit
Blood-Borne Infection Risk Assessment Unit
Risk Assessment Process
Rights and Responsibilities
Back
Back
Exit
Back
Publications
Publications
Publications
Subscribe to INSPQ's mailing lists
Exit
Back
Surveys
Surveys
Respiratory viruses survey
Respiratory viruses survey
Complete the survey (period from October 19 to 25, 2025)
Back
Exit
Back
Danger page
Search
Search by keywords
Content type
Content type
Data
Internship
Laboratory analysis
News
Newsletter
Page
Publication
Tiny Tot
Training
Vladimir Gilca
Publications
INSPQ
2022
Vaccination contre l’hépatite virale A suite à une éclosion à Nunavik
Calendrier de vaccination contre les virus du papillome humain pour les personnes âgées de 18 ans et plus au Québec
Fardeau de la varicelle et du zona à la suite de l’introduction du programme de vaccination contre la varicelle à une puis à deux doses au Québec
2020
Vaccination contre l’hépatite A des enfants nés d’avril 2013 à mai 2019
Les activités de vaccination en période de pandémie de COVID-2019 - Version 2.0 du 6 mai 2020
Mesures à mettre en place pour les hôtels qui accueilleront des personnes en isolement volontaire ou obligatoire (asymptomatiques) ou des personnes atteintes de COVID-19 ou sous investigation qui ne peuvent être isolées à la maison
2025
Protection contre les infections persistantes VPH 16/18 jusqu’à 13 ans après la vaccination de filles de 9-11 ans avec 2 ou 3 doses du vaccin quadrivalent selon un calendrier allongé : rapport de l’étude ICI-VPH
2021
SARS-CoV-2 transmission: Findings and proposed terminology
Transmission du SRAS-CoV-2 : constats et proposition de terminologie
2019
Groupes supplémentaires qui pourraient être visés par une vaccination gratuite contre les virus du papillome humain (VPH)
2016
Prévalence des infections au virus du papillome humain (VPH) : résultats de l’étude PIXEL - Portrait de la santé sexuelle des jeunes adultes au Québec, 2013-2014
2008
Prevention by vaccination of diseases attributable to the Human Papilloma Virus in Québec
2007
Prévention par la vaccination des maladies attribuables aux virus du papillome humain au Québec
Scientific papers
2025
Protection Against Persistent HPV-16/18 Infection After Different Number of Doses of Quadrivalent Vaccine in Girls and Young Women: A Randomized Clinical Trial
2022
The impact of influenza on the ability to work, volunteer and provide care: results from an online survey of Canadian adults 50 years and older
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study
2021
Sexual behavior, clinical outcomes and attendance of cervical cancer screening by HPV vaccinated and unvaccinated sexually active women
COVID-19's Impact on Willingness to Be Vaccinated against Influenza and COVID-19 during the 2020/2021 Season: Results from an Online Survey of Canadian Adults 50 Years and Older
2020
A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients
2019
The immune response to a two-dose schedule of quadrivalent HPV vaccine in 9-13 year-old girls: Is it influenced by age, menarche status or body mass index?
Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial
A mixed vaccination schedule of HPV vaccine induces a 100% seropositivity to all 9 HPV types included in 9vHPV vaccine
2018
Herpes Zoster Burden in Canadian Provinces: A Narrative Review and Comparison with Quebec Provincial Data
Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial
Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis
Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact
Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine
2017
Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Untangling the psychosocial predictors of HPV vaccination decision-making among parents of boys.
Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report.
2016
Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study.
2015
Global travel patterns and risk of measles in Ontario and Quebec, Canada:
Dramatic reduction in hepatitis B through school-based immunization without a routine infant program in a low endemicity region.
2013
Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine
Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine
2012
Determinants of parents' decision to vaccinate their children against rotavirus: results of a longitudinal study
Clinicians' opinions on new vaccination programs implementation
The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains
2011
Acute otitis media and its prevention by immunization: a survey of Canadian pediatricians' knowledge, attitudes and beliefs
Canadian paediatricians' opinions on rotavirus vaccination
A(H1N1) pandemic influenza and its prevention by vaccination: paediatricians' opinions before and after the beginning of the vaccination campaign
2010
Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine
2009
Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later
2008
Setting priorities for new vaccination programs by using public health officers and immunization managers opinions
2007
Vaccination against human papillomavirus: a baseline survey of Canadian clinicians' knowledge, attitudes and beliefs
Trends of hepatitis A hospitalization and risk factors in Quebec, Canada, between 1990 and 2003
2006
Impact of the quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program
2005
Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children
Nationwide canadian study of hepatitis a antibody prevalence among children eight to thirteen years old
Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country
Government of Quebec
Government of Quebec
